Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have earned an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $184.73.

Several analysts have weighed in on the stock. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, HC Wainwright dropped their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd.

Repligen Stock Performance

Shares of RGEN stock opened at $161.93 on Thursday. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of -437.64, a PEG ratio of 4.67 and a beta of 0.99. Repligen has a one year low of $113.50 and a one year high of $211.13. The company’s 50-day simple moving average is $155.02 and its 200-day simple moving average is $148.41. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the business posted $0.23 EPS. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities analysts anticipate that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Champlain Investment Partners LLC increased its stake in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after acquiring an additional 203,011 shares during the period. DF Dent & Co. Inc. increased its stake in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after acquiring an additional 139,615 shares during the period. Two Sigma Advisers LP raised its holdings in Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after purchasing an additional 102,100 shares in the last quarter. Finally, Fred Alger Management LLC lifted its position in Repligen by 29.5% in the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after purchasing an additional 90,831 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.